Benefit-risk assessment of the levonorgestrel intrauterine system in contraception

Drug Safety

Volumn 27, Issue 15, 2004, Pages 1185-1204

  Backman, Tiina ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER INTRAUTERINE DEVICE; ESTRADIOL; LEVONORGESTREL; PROGESTERONE; TAMOXIFEN;

ACNE; AMENORRHEA; BLEEDING DISORDER; BODY WEIGHT; BREAST FEEDING; BREAST TENDERNESS; CONTRACEPTION; COST EFFECTIVENESS ANALYSIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG RELEASE; DYSMENORRHEA; ECTOPIC PREGNANCY; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FEMALE; FEMALE FERTILITY; HAIR LOSS; HEADACHE; HORMONAL CONTRACEPTION; HORMONE SUBSTITUTION; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LACTATION; MENORRHAGIA; MENSTRUAL CYCLE; MENSTRUATION; MOOD DISORDER; OVARY FUNCTION; OVULATION; PAIN; PATIENT SATISFACTION; PELVIC INFLAMMATORY DISEASE; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TERATOGENESIS; WEIGHT GAIN;

ADMINISTRATION, INTRAVAGINAL; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; COST-BENEFIT ANALYSIS; FEMALE; FINLAND; HUMANS; INTRAUTERINE DEVICES, MEDICATED; LEVONORGESTREL; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; TIME FACTORS;

EID: 11244253976     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200427150-00003     Document Type: Review

References (173)

1. Product monograph. Berlin: Schering Oy, 2000
2. Sivin I, Mahgoub SE, Coutinho E, et al. Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20μg/day (LNg 20) and the Copper T 380Ag IUDs. Contraception 1991; 44: 473-80
3. Ratsula K, Toivonen J, Lahteenmaki P, et al. Plasma levonorgestrel levels and ovarian function during the use of a levonorgestrel-releasing intracervical contraceptive device. Contraception 1989; 39(2): 195-204
4. Luukkainen T, Allonen H, Haukkamaa M, et al. Five years' experience with levonorgestrel-releasing IUDs. Contraception 1986; 33: 139-48
5. Nilsson CG, Allonen H, Diaz J, et al. Two years experience with two levonorgestrel-releasing and one copper-releasing intrauterine device: a randomised comparative study. Fertil Steril 1983; 39: 187-92
6. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20μg/d and the copper Tcu 380Ag intrauterine contraceptive devices: a multicenter study: International Committee for Contraception Research (ICCR). Fertil Steril 1994; 61: 70-7
7. Bounds W, Robinson G. Clinical experience with a levonorgestrel releasing intrauterine contraceptive device (LNG IUD) as a contraceptive and in the treatment of menorrhagia. Br J Fam Plann 1993; 19: 193-4
8. Raudaskoski TH, Lahti EI, Kauppila AJ, et al. Transdermal estradiol with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses. Am J Obstet Gynecol 1995; 172: 114-9
9. Andersson K, Mattson LÅ, Rybo G, et al. Intrauterine release of levonorgestrel: a new way of adding progestogen in hormone replacement therapy. Obstet Gynecol 1992; 97: 963-7
10. Suhonen SP, Holmström T, Allonen HO, et al. Intrauterine and subdermal progestin administration in postmenopausal hormone replacement therapy. Fertil Steril 1995; 63: 336-42
11. Luukkainen T. Levonorgestrel-releasing intrauterine device. Ann N Y Acad Sci 1991; 626: 43-9
12. Xiao B, Zhou L, Ahang X, et al. Pharmacokinetic and pharmacodynamic studies of levonorgestrel-releasing intrauterine device. Contraception 1990; 41: 353-62
13. Nilsson CG, Lähteenmäki PLA, Luukkainen T, et al. Sustained intrauterine release of levonorgestrel over five years. Fertil Steril 1986; 84: 805-7
14. Nilsson CG, Haukkamaa M, Vierola H, et al. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol 1982; 17: 529-36
15. Weiner E, Victor A, Johansson EDB. Plasma levels of d-norgestrel after oral administration. Contraception 1976; 14: 563-70
16. Sivin I, Alvarez F, Mishell DR, et al. Contraception with two levonorgestrel rod implants: a five-year study in the United States and Dominican Republic. Contraception 1998; 58: 275-28
17. Sivin I, Mishell DR, Darney P, et al. Levonorgestrel capsule implants in the United States: a 5-year study. Obstet Gynecol 1998; 92: 337-44
18. Sturridge F, Guillebaud J. Gynaecological aspects of the levonorgestrel-releasing intrauterine system. Br J Obstet Gynaecol 1997; 104: 285-9
19. Jia M, Zhou L, Ren S, et al. Serun SHBG levels during normal menstrual cycle and after insertion of levonorgestrel-releasing IUD. Adv Contracept 1992; 8: 33-40
20. Nilsson CG, Lähteenmäki PL, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril 1984; 41: 52-5
21. Barbosa I, Bakos O, Olsson S-E, et al. Ovarian function during use of a levonorgestrel-releasing IUD. Contraception 1990; 42: 51-66
22. Silverberg SG, Haukkamaa M, Arko H, et al. Endometrial morphology during longterm use of levonorgestrel-releasing intrauterine devices. Int J Gynecol Pathol 1986; 5: 235-41
23. Jonsson B, Landgren B-M, Eneroth P. Effect of various IUDs on the composition of cervical mucus. Contraception 1991; 43: 447-58
24. Fraser IS, Tiitinen A, Affandi B, et al. Norplant®: consensus statement and background review. Contraception 1998; 57: 1-9
25. Ortiz ME, Croxatto HB. The mode of action of IUDs. Contraception 1987; 36: 37-53
26. Videla-Rivero L, Etchepareborda JJ, Kesseru E. Early chorionic activity in women bearing inert IUD, copper IUD and levonorgestrel-releasing IUD. Contraception 1987; 36: 217-26
27. Zhu P, Suo HZ, Xu RH, et al. The effect of intrauterine devices, the stainless steel ring, the Copper T220, and releasing levonorgestrel, on the bleeding profile and the morphological structure of the human endometrium: a comparative study of three IUDs: a morphometric study of 96 cases. Contraception 1989; 40: 425-38
28. Xiao BL, Zeng T, Wu S, et al. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use. Contraception 1995; 51: 359-65
29. Barbosa I, Olsson SE, Odlind V, et al. Ovarian function after seven years' use of a levonorgestrel IUD. Adv Contracept 1995; 11: 85-95
30. Rutanen E-M. Local is logical: effects of the levonorgestrel intrauterine system on the endometrium. In: Johansson EDB, editor. Mirena the levonorgestrel intrauterine system. New York: Parthnon Publishing Group, 1998: 33-9
31. Rutanen EM. Endometrial response to intrauterine release of levonorgestrel. Gynaecology Forum 1998; 3: 11-4
32. Jones RL, Critchley HO. Morphological and functional changes in human endometrium following intrauterine levonorgestrel delivery. Hum Reprod 2000; 15 Suppl. 3: 162-72
33. Nilsson CG, Luukkainen T, Arko H. Endometrial morphology of women using a D-norgestrel-releasing intrauterine device. Fertil Steril 1978; 29: 397-401
34. Critchely HOD, Wan H, Jones RL, et al. Morphological and functional features of endometrial decidualization following long-term intrauterine levonorgestrel delivery. Hum Reprod 1998; 13(5): 1218-24
35. Nilsson CG, Lähteenmäki P. Recovery of ovarian function after the use of a d-norgestrel-releasing IUD. Contraception 1977; 15: 389-400
36. Rutanen EM, Salmi A, Nyman T. mRNA expression of insulin-like growth factor-I (IGF-I) is suppressed and those of IGF-II and IGF-binding protein-I are constantly expressed in the endometrium during use of an intrauterine levonorgestrel system. Mol Hum Reprod 1997; 3: 749-54
37. Rutanen E-M, Hurskainen R, Finne P, et al. Induction of endometrial plasminogen activator-inhibitor 1: a possible mechanism contributing to the effect of intrauterine levonorgestrel in the treatment of menorrhagia. Fertil Steril 2000; 73: 1020-4
38. Mandelin E, Koistinen H, Koistinen R, et al. Levonorgestrel-releasing intrauterine device-esaring women express contraceptive glycodelin A in endometrium during midcycle: another contraceptive mechanism? Hum Reprod 1998; 12: 2671-5
39. Critchley HOD, Wang H, Kelly RW, et al. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system. Hum Reprod 1998; 13: 1210-7
40. Pakarinen PI, Suvisaari J, Luukkainen T, et al. Intracervical and fundal administration of levonorgestrel for contraception: endometrial thickness, patterns of bleeding and persisting ovarian follicles. Fertil Steril 1997; 68: 59-64
41. Jarvela I, Tekay A, Jouppila P. The effect of a levonorgestrel-releasing intrauterine system on uterine artery blood flow, hormone concentrations and ovarian cyst formation in fertile women. Hum Reprod 1998; 13: 3379-83
42. Lähteenmäki P, Rauramo I, Backman T. The levonorgestrel intrauterine system in contraception. Steroids 2000; 65: 693-7
43. Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years's comparative experience of levonorgestrel- and copper-releasing intrauterine devices. Obstet Gynecol 1991; 77: 261-4
44. Andersson K, Odlind V, Rybo F. Levonorgestrel-releasing and copper-releasing (NovaT®) IUDs during five years of use: a randomised comparative trial. Contraception 1994; 49: 56-72
45. Sivin I, El Mahgoub S, McCarthy T, et al. Long-term contraception with the levonorgestrel 20μg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomised study. Contraception 1990; 42: 361-78
46. Rosenberg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am J Obstet Gynecol 1998; 179: 577-82
47. Rosenberg M, Waugh MS. Causes and consequences of oral-contraceptive noncompliance. Am J Obstet Gynecol 1999; 180: 576-9
48. Pakarinen PI, Toivonen J, Luukkainen T. Therapeutic use of the LNG IUS and counselling. Semin Reprod Med 2001; 18: 365-72
49. Indian Council of Medical Research. Task force on IUD: randomized clinical trial with intrauterine devices (levonorgestrel) intrauterine device (LNG), CuT 380Ag, CuT 220C and CuT 200B): a 36-month study. Contraception 1989; 39: 37-52
50. Scholten P, Christiaens GCML, Alsbach GPJ, et al. Clinical experience with a levonorgestrel intrauterine device. In: Scholten PC, editor. The levonorgestrel IUD: clinical performance and impact on menstruation [thesis]. Utrecht: University Hospital, 1989: 71-84
51. Faundes A, Alvarez F, Diaz J. A Latin American experience with levonorgestrel IUD. Ann Med 1993; 25: 149-53
52. Diaz J, Faundes A, Diaz M, et al. Evaluation of the clinical performance of a levonorgestrel-releasing IUD, up to seven years of use, in Campinas, Brazil. Contraception 1993; 47 (2): 169-75
53. Cox M, Tripp J, Blacksell S. Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care 2002; 28 (2): 73-7
54. Backman T, Huhtala S, Rauramo I, et al. Pregnancies during the use of the levonorgestrel-releasing intrauterine system. Am J Obstet Gynecol 2004; 191: 50-4
55. Gao J, Wang S-I, Wu S-C, et al. Comparison of the clinical performance, contraceptive efficacy and acceptability of levonorgestrel-releasing IUD and Norplant®-II implants in China. Contraception 1990; 41: 485-94
56. Wang SL, Su SC, Xin XM, et al. Three years' experience with levonorgestrel-releasing intrauterine device and Norplant-2 implants: a randomized comparative study. Adv Contracept 1992; 8: 105-14
57. Luukkainen T, Allonen H, Nielsen N-C, et al. Five years' experience of intrauterine contraception with the Nova-T and the Copper-T-200. Am J Obstet Gynecol 1983; 147: 885-91
58. Vessey MP, Lawless M. The Oxford-Family Planning Association contraceptive study. Clin Obstet Gynecol 1984; 11 (3): 743-57
59. Chi I-C. The progestin-only pills and the levonorgestrel-releasing IUD: two progestin-only contraceptives. Cl Obstet Gynecol 1995; 38: 872-89
60. Foreman H, Stadel BV, Schlesselman S. Intrauterine device usage and fetal loss. Obstet Gynecol 1981; 58: 669-77
61. Tatum HJ, Schmidt FH, Jain AD. Management and outcome of pregnancies associated with the copper T intrauterine contraceptive device. Am J Obstet Gynecol 1976; 7: 869-79
62. Sivin I. Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet Gynecol 1991; 78: 291-8
63. Mishell DR. Intrauterine devices: mechanisms of action, safety and efficacy. Contraception 1998; 58: 45S-53S
64. Meirik O, Parley TMM, Sivin I, et al. Safety and efficacy of levonorgestrel implant, intrauterine device and sterilization. Obstet Gynecol 2001; 97: 539-47
65. Franks AL, Beral V, Gates W, et al. Contraception and ectopic pregnancy risk. Am J Obstet Gynecol 1990; 163: 1120-3
66. Trivedi AN, Ngu A. Failed cervical pregnancy with levonorgestrel containing intrauterine contraceptive device. Aust N Z J Obstet Gynaecol 2002; 42: 210-21
67. Richardson S. Ectopic pregnancy in a Mirena user [letter]. Br J Fam Plann 1998; 23: 141
68. Gebble A, Brown A, Pearson S. Ectopic pregnancy in a Mirena user [letter]. Br J Fam Plann 1997; 23: 69
69. Masters T, Miskry T, Lowe D, et al. Report of ectopic pregnancies associated with levonorgestrel intrauterine system. Br J Fam Plann 1997; 23: 25-6
70. Pharriss BB, Erickson R, Bashaw J, et al. Progestasert®: a uterine therapeutic system for long-term contraception: 1. Philosophy and clinical efficacy. Fertil Steril 1974; 25: 915-21
71. Xiao BL, Gu SJ, Wang SL, et al. NORPLANT and the levonorgestrel IUD in Chinese family planning programmes. Ann Med 1993; 25: 161-5
72. Batar I, Kuukankorpi A, Siljander M, et al. Five-year clinical experiences with NOVA T® copper IUD. Contraception 2002; 66: 309-14
73. Hidalgo M, Bahamondes L, Perrotti M, et al. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years. Contraception 2002; 65: 129-32
74. Chi C, Wilkens L, Rogers S. Expulsions in immediate postpartum insertions of Lippes Loop D and Copper T and their counterpart Delta devices. Contraception 1986; 34: 119-33
75. Lee NC, Rubin GL, Borucki R. The intrauterine device and pelvic inflammatory disease revisited: new results from the Women's Health Study. Obstet Gynecol 1988; 72: 1-6
76. Andersson K, Batar I, Rybo G. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. Contraception 1992; 46: 575-84
77. Sivin I, Stern J, Diaz S, et al. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices. Contraception 1992; 166: 1208-13
78. Belhadj H, Sivin I, Diaz S, et al. Recovery of fertility after use of the levonorgestrel 20μg/d or Copper T 380Ag intrauterine device. Contraception 1986; 34: 261-7
79. Nilsson CG. Fertility after discontinuation of levonorgestrel releasing intrauterine device. Contraception 1982; 25: 273-8
80. Doll H, Vessey M, Painter R. Return of fertility in nulliparous women after discontinuation of the intrauterine device: comparison with women discontinuing other methods of contraception. BJOG 2001; 108: 304-14
81. Sturridge F, Guillebaud J. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system. Drug Saf 1996; 15 (6): 430-40
82. Luukkainen T, Toivonen J. Levonorgestrel-releasing IUD as a method of contraception with therapeutic properties. Contraception 1995; 52: 269-76
83. Kaunitz AM. Reappearance of the intrauterine device: a "user-friendly" contraceptive. Int J Fertil Womens Med 1997; 42 (2): 120-7
84. Sivin I, Alvarez F, Diaz J, et al. Intrauterine contraception with copper and with levonorgestrel: a randomized study of the Tcu 380Ag and levonorgestrel 20μg/day. Contraception 1984; 30: 443-56
85. Suhonen S, Haukkamaa M, Jakobsson T, et al. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young, nulliparous women: a comparative study. Contraception 2004; 69: 407-12
86. Harrison-Woolrych M, Zhou L, Coulter D. Insertion of intrauterine devices: a comparison of experience with Mirena and Multiload Cu375 during post-marketing monitoring in New Zealand. NZMJ 2003; 116: 1-7
87. Ollila E, Sihvo S, Meriläinen J, et al. Experience of Finnish women with Norplant insertions and removals. Br J Obstet Gynaecol 1998; 92: 337-44
88. Implanon product monograph. Roseland (NJ): Organon, 2002
89. Ronnerdag M, Odlind V. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. Acta Obstet Gynecol Scand 1999; 78: 716-21
90. Andersson K, Ryde-Blomqvist E, Lindell K, et al. Perforation with intrauterine devices report from a Swedish survey. Contraception 1998; 57: 251-5
91. Silva PD, Larsson KM. Laparoscopic removal of a perforated intrauterine device from the pererectal fat. J Soc Laparosc Surg 2000; 4: 159-62
92. Haimov-Kochman R, Doviner V, Amsalem H, et al. Intraperitoneal levonorgestrel-releasing intrauterine device following uterine perforation: the role of progestins in adhesion formation. Hum Reprod 2003; 18: 990-3
93. Heikkilä M, Lahteenmaki P, Luukkainen T. Immediate postabortal insertion of a levonorgestrel-releasing IUD. Contraception 1982; 26: 245-59
94. Heikkilä M. Puerperal insertion of a copper-releasing and a levonorgestrel-releasing intrauterine contraceptive device. Contraception 1982; 25: 561-72
95. Kiilholma P, Mäkinen J, Vuori J. Bladder perforation: uncommon complication with a misplaced IUD. Adv Contracept 1989; 5: 47-9
96. Dennis J, Hampton N. IUDs: which device? J Fam Plann Reprod Health Care 2002; 28 (2): 61-8
97. Parley TNM, Rosenberg MJ, Rowe PJ, et al. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992; 339: 875-8
98. Tsanadis G, Kalantaridou N, Kaponis A, et al. Bacteriological cultures of removed intrauterine devices and pelvic inflammatory disease. Contraception 2002; 65: 339-42
99. Fortney JA, Feldblum PJ, Raymond EG. Intrauterine devices the optimal long-term contraceptive method? J Reprod Med 1999; 44: 269-73
100. Grimes DA. Intrauterine device and upper-genital-tract infection. Lancet 2000; 356: 1013-20
101. Croxatto HB, Diaz S, Salvatierra AM, et al. Treatment with Norplant subdermal implants inhibits sperm penetration through cervical mucus in vitro. Contraception 1987; 36: 193-201
102. Fiorino AS. Intrauterine contraceptive device-associated actinomycotic abscess and actinomyces detection on cervical smear. Obstet Gynecol 1996; 87: 142-9
103. Lippes J. Pelvic actinomycosis: a review and preliminary look at prevalence. Am J Obstet Gynecol 1999; 180: 2665-9
104. Merki-Feld GS, Lebeda E, Hogg B, et al. The incidence of Actinomyces-like organisms in Papanicolaou-stained smears of copper- and levonorgestrel- releasing intrauterine devices. Contraception 2000; 61: 365-8
105. Luukkainen T. The levonorgestrel releasing IUD. Br J Fam Plann 1993; 19: 221-4
106. Nilsson CG, Kostiainen E, Ehnholm C. Serum lipids high-density- lipoprotein cholesterol in women on long-term sustained low-dose IUD treatment with levonorgestrel. Int J Fertil 1981; 26(2): 135-7
107. Pakarinen P, Lähteenmäki P, Rutanen EM. The effect of intrauterine and oral levonorgestrel administration on seurn concentrations of sex hormone-binding globulin, insulin and insulin-like growth factor binding protein-1. Acta Obstet Gynecol Scand 1999; 78: 423-8
108. Hatasaka H. Implantable levonorgestrel contraception: 4 years of experience with Norplant. Clin Obstet Gynecol 1995; 38: 859-71
109. Tayob Y, Adams J, Jacobs H, et al. Ultrasond demonstration of increased frequency of functional ovarian cysts in women using progestogen-only oral contraception. Br J Obstet Gynaecol 1985; 92: 1003-9
110. Robinson G, Bound W, Kubba A, et al. Functional ovarian cysts associated with the levonorgestrel-releasing intrauterine device. Br J Fam Plann 1989; 14: 131-2
111. Johansson E, Odlind V. The passage of exogenous hormones into breast milk: possible effects. Int J Gynaecol Obstet 1987; 25 Suppl. 1: 111-4
112. Baheiraei A, Ardsetani N, Ghazizadeh S. Effects of progestogen-only contraceptives on breast-feeding and infant growth. Int J Obstet Gynaecol 2001; 74: 203-5
113. Heikkilä M, Luukkainen T. Duration of breast-feeding and development of children after insertion of a levonorgestrel-releasing intrauterine contraceptive device. Contraception 1982; 25: 279-92
114. McCann MF, Moggia AV, Higgins JE, et al. The effects of a progestin-only oral contraceptive (levonorgestrel 0.03mg) on breast-feeding. Contraception 1989; 40: 635-48
115. World Health Organization Task Force for Epidemiological Research on Reproductive Health Special Programme of Research Development and Research Training in Human Reproduction. Progestogen-only contraceptives during lactation: I. Infant growth. Contraception 1994; 50: 35-53
116. World Health Organization Task Force for Epidemiological Research on Reproductive Health Special Programme of Research Development and Research Training in Human Reproduction. Progestogen-only contraceptives during lactation: II. Infant development. Contraception 1994; 50: 55-68
117. Heikkilä M, Haukkamaa M, Luukkainen T. Contraception with a levonorgestrel-releasing IUD: effect on lactation and child development. In: Zatuchni GI, Goldsmilt A, Shelton JD, et al., editors. Long-acting contraceptive delivery systems. Philadelphia (PA): Harper and Row, 1984: 368-77
118. Lo JC, Schwitzgebel VM, Tyrrell JB, et al. Normal female infants born of mothers with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1999; 84: 930-6
119. Abbott DH, Dumesic DA, Franks S. Developmental origin of polycystic ovary syndrome: a hypothesis. J Endocrinol 2002; 174: 1-5
120. Suvisaari J, Lähteenmäki P. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system. Contraception 1996; 54: 201-8
121. Ji G, Wang S, Wu B, et al. Comparison of the clinical performance, contraceptive efficacy and acceptability of levonorgestrel-releasing IUD and NORPLANT implants in China. Contraception 1990; 41: 353-62
122. Baldaszti E, Wimmer-Puchinger B, Löschke K. Acceptability of the long-term contraceptive levonorgestrel-releasing intrauterine system (Mirena®): a 3-year follow-up study. Contraception 2003; 67: 87-91
123. Backman T, Huhtala S, Blom T, et al. Length of use and symptoms associated with premature removal of the levonorgestrel intrauterine system: a nation-wide study of 17 360 users. Br J Obstet Gynecol 2000; 107: 335-9
124. Brechin S, Cameron ST, Paterson AM, et al. Intrauterine polyps: a cause of unscheduled bleeding in women using the levonorgestrel intrauterine system. Hum Reprod 2000; 15: 650-2
125. Andersson K, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol 1990; 97: 690-4
126. Faundes A, Alvarez F, Brache V, et al. The role of the levonorgestrel intrauterine device in the prevention and treatment of iron deficiency anemia during fertility regulation. Int J Gynecol Obstet 1988; 26: 429-33
127. Tang GWK, Lo SST. Levonorgestrel intrauterine device in the treatment of menorrhagia in Chinese women: efficacy versus acceptability. Contraception 1995; 51: 231-5
128. Glasier AF, Smith KB, van der Psuy ZM, et al. Amenorrhea associated with contraception: an international study on acceptability. Contraception 2003; 67: 1-8
129. Thomas SL, Ellertson C. Nuisance or natural and healthy: should monthly menstruation be optional for women? Lancet 2000; 355 (9207): 922-5
130. Coulter A, Bradlow J, Agass M, et al. Outcomes of referrals to gynaecology outpatient clincs for menstrual problems: an audit of general practice records. Br J Obstet Gyneacol 1991; 98: 789-96
131. Vessey MP, Villard-Macintosh I, McPherson K, et al. The epidemiology of hysterectomy, findings in a large cohort study. Br J Obstet Gynaecol 1992; 99: 402-7
132. Den Tonkelaar I, Oddens BJ. Preferred frequency and characteristics of menstrual bleeding in relation to reproductive status, oral contraceptive use and hormone replacement therapy use. Contraception 1999; 59: 357-62
133. Datey S, Gaur LN, Saxena BN. Vaginal bleeding patterns of women using different contraceptive methods (implants, injectables, IUDs, oral pills): an Indian experience. Contraception 1995; 51: 155-65
134. Heath CB, Sulik S. Contraception and preconception counselling. Womens Health 1997; 24: 123-33
135. Shain RN, Ratsula K, Toivonen J, et al. Acceptability of an experimental intracervical device; results of a study controlling for selection bias. Contraception 1989; 39: 73-84
136. Oddens BJ. Women's satisfaction with birth control: a population survey of physical and psychological effects of oral contraceptives, intrauterine devices, condoms, natural family planning and sterilization among 1466 women. Contraception 1999; 59: 277-86
137. Haughen MM, Evans CB, Kim MH. Patient satisfaction with a levonorgestrel-releasing contraceptive implant reasons for and patterns of removal. J Reprod Med 1996; 41: 849-54
138. Rivera R, Chen-Mok M, McMullen S. Analysis of client characteristics that may affect early discontinuation of the Tcu 380Ag IUD. Contraception 1999; 60: 155-60
139. Fleming D, Davie J, Glasier A. Continuation rates of long-acting methods of contraception: a comparative study of Norplant implants and intrauterine devices. Contraception 1998; 57: 19-21
140. Coukell AJ, Balfour JA. Levonorgestrel subdermal implants: a review of contraceptive efficacy and acceptability. Drugs 1998; 56 (6): 861-87
141. Vekemans M, Delvigne A, Paesmans M. Continuation rates with a levonorgestrel-releasing contraceptive implant (Norplant®: a prospective study in Belgium. Contraception 1997; 56: 291-9
142. Dubuisson JB, The Mirena Study Group, Mugnier E. Acceptability of the levonorgestrel-releasing intrauterine system after discontinuation of previous contraception: results of a French clinical study in women aged 35 to 45 years. Contraception 2002; 66: 121-8
143. Luukkainen T, Allonen H, Haukkamaa M, et al. Effective contraception with the levonorgestrel-releasing intrauterine device: a 12-month report of a European multicentre study. Contraception 1987; 36: 169-79
144. Sivin I, Stern J, Diaz J, et al. Two years of intrauterine contraception with levonorgestrel and with copper: a randomised comparison of the Tcu 380Ag and levonorgestrel 20ug/day devices. Contraception 1987; 35: 245-55
145. Davie JE, Walling MR, Mansour DJ, et al. Impact of patient counseling on acceptance of the levonorgestrel implant contraceptive in the United Kingdom. Clin Ther 1996; 18: 150-9
146. Backman T, Huhtala S, Luoto R, et al. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet Gynecol 2002; 99: 608-13
147. Brache V, Faundes A, Alvarez F, et al. Nonmenstrual adverse events during use of implantable contraceptives for women: data from clinical trials. Contraception 2002; 65: 63-74
148. Coleman M, McCowan L, Farquhar C. The levonorgestrel-releasing intrauterine device: a wider role than contraception. Aust N Z J Obstet Gynaecol 1997; 37: 195-201
149. Chiou C-F, Trussell J, Reyes E, et al. Economic analysis of contraceptives for women. Contraception 2003; 68: 3-10
150. Trussell J, Leveque J, Koenig J, et al. The economic value of contraception: a comparison of 15 methods. Am J Public Health 1995; 85: 494-503
151. Milsom I, Andersson K, Andersch B, et al. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia. Am J Obstet Gynecol 1991; 164: 879-83
152. Hurskainen R, Teperi J, Rissanen P, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial follow-up. JAMA 2004; 291: 1456-63
153. Pharmaca Fennica manual. Helsinki: Pharma Industry, 2004
154. Luoto R, Kaprio J, Keskimäki I, et al. Incidence, causes and surgical methods for hysterectomy in Finland. Int J Epidemiol 1994; 23: 348-58
155. Hurskainen R, Teperi J, Rissanen P, et al. Quality of life and cost-effectiveness of levonorgestrel-releasing intrauterine system versus hysterectomy for treatment of menorrhagia: a randomised trial. Lancet 2001; 357: 273-7
156. Barrington JW, Bowen-Simkins P. The levonorgestrel intrauterine system in the management of menorrhagia. Br J Obstet Gynaecol 1997; 104: 614-6
157. Irvine GA, Campbell-Brown MB, Lumsden MA, et al. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 1998; 105: 592-8
158. O'Connor H, Broadment J, Magos A, et al. Medical research council randomised trial of endometrial resection versus hysterectomy in management of menorrhagia. Lancet 1997; 349: 897-901
159. Istre O, Trolle B. Treatment of menorrhagia with the levonorgestrel intrauterine system vs endometrial resection. Fertil Steril 2001; 76: 304-9
160. Crosignani PG, Vercellini P, Mosconi P, et al. Levonorgestrel-releasing intrauterine device versus hysteroscopic endometrial resection in the treatment of dysfunctional uterine bleeding. Obstet Gynecol 1997; 90: 257-63
161. Marjoribanks J, Lethaby A, Farquahr C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev 2003; (2): CD003855
162. Chi IC. An evaluation of the levonorgestrel-releasing IUD: its advantages and disadvantages when compared to the copper-releasing IUDs. Contraception 1991; 44: 573-88
163. Vercellini P, Aimi G, Panazza S, et al. A levonorgestrel-releasing intrauterine system for the treatment of dysmenorrhea associated with endometriosis: a pilot study. Fertil Steril 1999; 72: 505-8
164. Fedele L, Bianchi S, Zanconato G, et al. Use of a levonorgestrel- releasing intrauterine device in the treatment of rectovaginal endometriosis. Fertil Steril 2001; 75: 485-8
165. Fong YF, Singh K. Medical treatment of a grossly enlarged adenomyotic uterus with the levonorgestrel-releasing intrauterine system. Contraception 1999; 60: 173-5
166. Fedele L, Bianchi S, Raffaelli R, et al. Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device. Fertil Steril 1997; 68: 426-9
167. Perino A, Quartararo P, Catinella E, et al. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Eur Feril 1987; 18: 137-40
168. Scarselli G, Tantini C, Colafranceschi M, et al. Levo-norgestrel-Nova-T and precancerous lesions of the endometrium. Eur J Gynaecol Oncol 1988; 4: 284-6
169. Feeley KM, Wells M. Hormone replacement therapy and the endometrium. J Clin Pathol 2001; 54: 435-40
170. Suhonen SP, Allonen HO, Lähteenmäki P. Sustained-release estradiol implants and a levonorgestrel-releasing intrauterine device in hormone replacement therapy. Am J Obstet Gynecol 1995; 172: 562-7
171. Suvanto-Luukkonen E, Sundström H, Penttinen J, et al. Endometrial morphology during hormone replacement therapy with estradiol gel combined with to levonorgestrel-releasing intrauterine device or natural progesterone. Acta Obstet Gynecol Scand 1998; 77: 758-63
172. Neven P, De Muylder X, Van Belle Y, et al. Tamoxifen and the uterus. BMJ 1994; 309: 1313-4
173. Gardner FJE, Konje JC, Abrams KR, et al. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. Lancet 2000; 356: 1711-7